

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JC20 Rec'd PCT/PTO 21 OCT 2005

Applicant:	Mark T. Bilodeau, et al.
Attorney Docket No.	21299YP
PCT Appl. No.:	PCT/US04/012188 Filed: 20 April 2004
Filing Date:	October 21, 2005
For:	INHIBITORS OF AKT ACTIVITY

Art Unit:
To be determined**Examiner:**
To be determined

Mail Stop: PCT
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

LETTER

Sir:


In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases: Application Disclosures Containing Nucleotide And/Or Amino Acid Sequences, the signature page and following statement are being submitted herewith.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

The enclosed diskette contains the Sequence Listing for case number 21299YP.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT Oct. 21, 2005
EXPRESS MAIL NO. EV4213439105
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY Linda Zeller
DATE October 21, 2005

Respectfully submitted,

By: 
Matthew A. Leff
Registration No. 50,149
Attorney for Applicants

Merck & Co., Inc.
P.O. Box 2000 – RY 60-30
Rahway, New Jersey 07065-0907
Telephone No. (732) 594-1404

Date: October 21, 2005